Loading...
Please wait, while we are loading the content...
Similar Documents
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL
| Content Provider | Scilit |
|---|---|
| Author | Goy, Andre Ramchandren, Radhakrishnan Ghosh, Nilanjan Munoz, Javier Morgan, David S. Dang, Nam H. Knapp, Mark Delioukina, Maria Kingsley, Edwin Ping, Jerry Beaupre, Darrin M. Neuenburg, Jutta K. Ruan, Jia |
| Copyright Year | 2019 |
| Description | The investigators report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide in patients with relapsed non–germinal center diffuse large B-cell lymphoma (DLBCL). |
| Related Links | https://ashpublications.org/blood/article-pdf/134/13/1024/1222966/blood891598.pdf |
| Ending Page | 1036 |
| Page Count | 13 |
| Starting Page | 1024 |
| DOI | 10.1182/blood.2018891598 |
| Journal | Blood |
| Issue Number | 13 |
| Volume Number | 134 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2019-09-26 |
| Access Restriction | Open |
| Subject Keyword | Hematology Promising Plus Lenalidomide Triplet Rituximab Therapy Triplet Investigators Report Cell Lymphoma Ibrutinib Plus Journal: Blood (Vol- 123, Issue- 13) |
| Content Type | Text |
| Resource Type | Article |